Huanming Chen is the Co-founder, President, and Chief Executive Officer of Zhimeng Biopharma. Dr. Chen is an expert in drug discovery and medicinal chemistry. He had held numerous leadership positions previously in both pharmaceutical industry and Contractual Research Organizations (CROs). Prior to starting Zhimeng Biopharma, Dr. Chen served as the Vice President of Chemistry at Medicilon, Inc., Shanghai, China, responsible for drug discoveries and contracted services for pharmaceutical companies worldwide. Under Dr. Chen's leadership, despite the increasing competition of the CRO service sector, the revenues of the chemistry business at Medicilon maintained about 50% increase for 4 consecutive years, and the number of employees also increased 4 times with much improved capacity. Before joining Medicilon, Dr. Chen was the Head of Shanghai R&D Center at Simcere, Inc., overseeing the center's setting up and operation, research and development of innovative medicines to treat CNS and oncology diseases. Dr. Chen served as a Senior Director of chemistry at BioDuro, a CRO in Beijing, China. Prior to BioDuro, Dr. Chen was at Valeant Pharmaceutical Internationals, US, and its spun-off company Ardea Biosciences, US, with increasing responsibilities in drug discoveries for HIV, HBV, HCV, oncology, and CNS diseases.
In his productive career, Dr. Chen has led the discoveries and development of more than 10 pre-clinical and clinical products for antiviral, anticancer, CNS, and inflammation. He has authored/co-authored 36 publications and 35 patents.
Dr. Chen obtained his Ph.D. in medicinal chemistry from China Pharmaceutical University (Nanjing, China) and received his post-doctoral training at University of Maryland, USA.